ACCELERON PHARMA INC. Forms 3, 4 and 5: Stock Options
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 27 rows in 2019. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2019-07-09: Reporting owner Quisel John D; Form 4; Security Option to Purchase Common Stock; Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2019-07-09: Reporting owner Quisel John D; Form 4; Security Option to Purchase Common Stock; Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2019-07-09: Reporting owner Quisel John D; Form 4; Security Option to Purchase Common Stock; Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
- 2019-06-26: Reporting owner George Jean; Form 4; Security Option to Purchase Common Stock; Transaction M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2019-07-09 | Quisel John D Officer (EVP, Chief Business Officer) | 4 | Option to Purchase Common Stock Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −5,000 0 owned after | $3.88 exercise price | 2019-07-11 | |
| 2019-07-09 | Quisel John D Officer (EVP, Chief Business Officer) | 4 | Option to Purchase Common Stock Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −2,346 0 owned after | $5.28 exercise price | 2019-07-11 | |
| 2019-07-09 | Quisel John D Officer (EVP, Chief Business Officer) | 4 | Option to Purchase Common Stock Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −1,562 0 owned after | $7.12 exercise price | 2019-07-11 | |
| 2019-06-26 | George Jean Director | 4 | Option to Purchase Common Stock Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −20,000 0 owned after | $24.11 exercise price | 2019-06-28 | |
| 2019-06-26 | George Jean Director | 4 | Option to Purchase Common Stock Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −10,000 0 owned after | $27.97 exercise price | 2019-06-28 | |
| 2019-06-26 | George Jean Director | 4 | Option to Purchase Common Stock Derivative · Direct | M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | −7,500 0 owned after | $30.17 exercise price | 2019-06-28 | |
| 2019-06-07 holding as of filing | Veness Adam M Officer (VP, General Counsel and Sec.) | 3 | Option to Purchase Common Stock Derivative · Direct | Holding | $41.64 exercise price | 2019-06-07 | ||
| 2019-06-07 holding as of filing | Veness Adam M Officer (VP, General Counsel and Sec.) | 3 | Option to Purchase Common Stock Derivative · Direct | Holding | $40.61 exercise price | 2019-06-07 | ||
| 2019-06-07 holding as of filing | Veness Adam M Officer (VP, General Counsel and Sec.) | 3 | Option to Purchase Common Stock Derivative · Direct | Holding | $30.17 exercise price | 2019-06-07 | ||
| 2019-06-07 holding as of filing | Veness Adam M Officer (VP, General Counsel and Sec.) | 3 | Option to Purchase Common Stock Derivative · Direct | Holding | $27.97 exercise price | 2019-06-07 | ||
| 2019-06-07 holding as of filing | Veness Adam M Officer (VP, General Counsel and Sec.) | 3 | Option to Purchase Common Stock Derivative · Direct | Holding | $41.20 exercise price | 2019-06-07 | ||
| 2019-06-07 holding as of filing | Veness Adam M Officer (VP, General Counsel and Sec.) | 3 | Option to Purchase Common Stock Derivative · Direct | Holding | $29.37 exercise price | 2019-06-07 | ||
| 2019-06-05 | Veness Adam M Officer (VP, General Counsel and Sec.) | 4 | Option to Purchase Common Stock Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +6,700 6,700 owned after | $40.37 exercise price | 2019-06-07 | |
| 2019-01-25 | Zakrzewski Joseph S Director | 4 | Option to Purchase Common Stock Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +7,500 7,500 owned after | $41.64 exercise price | 2019-01-29 | |
| 2019-01-25 | Smith Karen L. Director | 4 | Option to Purchase Common Stock Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +7,500 7,500 owned after | $41.64 exercise price | 2019-01-29 | |
| 2019-01-25 | POPS RICHARD F Director | 4 | Option to Purchase Common Stock Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +7,500 7,500 owned after | $41.64 exercise price | 2019-01-29 | |
| 2019-01-25 | MCCOURT Thomas A Director | 4 | Option to Purchase Common Stock Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +7,500 7,500 owned after | $41.64 exercise price | 2019-01-29 | |
| 2019-01-25 | Maniatis Tom Director | 4 | Option to Purchase Common Stock Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +7,500 7,500 owned after | $41.64 exercise price | 2019-01-29 | |
| 2019-01-25 | Kearney Terrence C Director | 4 | Option to Purchase Common Stock Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +7,500 7,500 owned after | $41.64 exercise price | 2019-01-29 | |
| 2019-01-25 | George Jean Director | 4 | Option to Purchase Common Stock Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +7,500 7,500 owned after | $41.64 exercise price | 2019-01-29 | |
| 2019-01-25 | Nader Francois Director | 4 | Option to Purchase Common Stock Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +7,500 7,500 owned after | $41.64 exercise price | 2019-01-29 | |
| 2019-01-25 | Kumar Ravindra Officer (SVP & Chief Scientific Officer) | 4 | Option to Purchase Common Stock Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +21,500 21,500 owned after | $41.64 exercise price | 2019-01-29 | |
| 2019-01-25 | KANGO SUJAY Officer (SVP, Chief Commercial Officer) | 4 | Option to Purchase Common Stock Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +25,500 25,500 owned after | $41.64 exercise price | 2019-01-29 | |
| 2019-01-25 | Quisel John D Officer (EVP, CBO and Secretary) | 4 | Option to Purchase Common Stock Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +28,500 28,500 owned after | $41.64 exercise price | 2019-01-29 | |
| 2019-01-25 | Zeldin Robert K Officer (EVP & Chief Medical Officer) | 4 | Option to Purchase Common Stock Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +13,000 13,000 owned after | $41.64 exercise price | 2019-01-29 | |
| 2019-01-25 | MCLAUGHLIN KEVIN F Officer (SVP, CFO and Treasurer) | 4 | Option to Purchase Common Stock Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +28,000 28,000 owned after | $41.64 exercise price | 2019-01-29 | |
| 2019-01-25 | Dable Habib J Director, Officer (CEO and President) | 4 | Option to Purchase Common Stock Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +106,400 106,400 owned after | $41.64 exercise price | 2019-01-29 |